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Abstract: Background aims: A common genetic variant near MBOAT7 (rs641738C>T) has been previ-
ously associated with hepatic fat and advanced histology in non-alcoholic fatty liver disease (NAFLD),
however, these findings have not been consistently replicated in the literature. We aimed to establish
whether rs641738C>T is a risk factor across the spectrum of NAFLD and characterize its role in the reg-
ulation of related metabolic phenotypes through meta-analysis. Methods: We performed meta-analysis
of studies with data on the association between rs641738C>T genotype and: liver fat, NAFLD histology,
and serum ALT, lipids, or insulin. These included directly genotyped studies and population-level data
from genome-wide association studies (GWAS). We performed random effects meta-analysis using reces-
sive, additive, and dominant genetic models. Results: Data from 1,066,175 participants (9,688 with liver
biopsies) across 42 studies were included in the meta-analysis. rs641738C>T was associated with higher
liver fat on CT/MRI (+0.03 standard deviations [95% CI: 0.02 - 0.05], pz=4.8x10-5) and diagnosis of
NAFLD (OR 1.17 [95% CI 1.05 - 1.3], pz=0.003) in Caucasian adults. The variant was also positively
associated with presence of advanced fibrosis (OR 1.22 [95% CI: 1.03 - 1.45], pz=0.021) in Caucasian
adults using a recessive model of inheritance (CC+CT vs. TT). Meta-analysis of data from previous
GWAS found the variant to be associated with higher ALT (pz=0.002) and lower serum triglycerides
(pz=1.5x10-4). rs641738C>T was not associated with fasting insulin and no effect was observed in chil-
dren with NAFLD. Conclusion: Our study validates rs641738C>T near MBOAT7 as a risk factor for the
presence and severity of NAFLD in individuals of European descent.
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Background & Aims 
A common genetic variant near MBOAT7 (rs641738C>T) has been previously 
associated with hepatic fat and advanced histology in non-alcoholic fatty liver 












replicated in the literature. We aimed to establish whether rs641738C>T is a 
risk factor across the spectrum of NAFLD and characterize its role in the 
regulation of related metabolic phenotypes through meta-analysis. 
Methods 
We performed meta-analysis of studies with data on the association between 
rs641738C>T genotype and: liver fat, NAFLD histology, and serum ALT, 
lipids, or insulin. These included directly genotyped studies and population-
level data from genome-wide association studies (GWAS). We performed 
random effects meta-analysis using recessive, additive, and dominant genetic 
models. 
Results 
Data from 1,066,175 participants (9,688 with liver biopsies) across 42 studies 
were included in the meta-analysis. rs641738C>T was associated with higher 
liver fat on CT/MRI (+0.03 standard deviations [95% CI: 0.02 - 0.05], 
pz=4.8x10
-5) and diagnosis of NAFLD (OR 1.17 [95% CI 1.05 - 1.3], pz=0.003) 
in Caucasian adults. The variant was also positively associated with presence 
of advanced fibrosis (OR 1.22 [95% CI: 1.03 - 1.45], pz=0.021) in Caucasian 
adults using a recessive model of inheritance (CC+CT vs. TT). Meta-analysis 
of data from previous GWAS found the variant to be associated with higher 
ALT (pz=0.002) and lower serum triglycerides (pz=1.5x10
-4). rs641738C>T 
was not associated with fasting insulin and no effect was observed in children 
with NAFLD. 
Conclusion 
Our study validates rs641738C>T near MBOAT7 as a risk factor for the 














Fatty liver disease is a common condition where fat builds up in the liver, 
which can cause liver inflammation and scarring (including ‘cirrhosis’). It is 
closely linked to obesity and diabetes, but some genes are also thought to be 
important. We did this study to see whether one specific change (‘variant’) in 
one gene (‘MBOAT7’) was linked to fatty liver disease. We took data from 
over 40 published studies and found that this variant near MBOAT7 is linked 
to more severe fatty liver disease. This means that drugs designed to work on 
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HIGHLIGHTS 
● Meta-analysis of 42 studies (>1 million participants) for the role of 
rs641738C>T near MBOAT7 on NAFLD 
● rs641738C>T positively associated with liver fat, ALT, fibrosis, and 
HCC 
● rs641738C>T negatively associated with serum triglycerides 














Since the first genome-wide association study (GWAS) of liver fat[1], more 
than 20 genetic single nucleotide variants (SNVs) have been associated with 
non-alcoholic fatty liver disease (NAFLD)[2]. These studies have deepened 
our understanding of the condition, its heritability, and its relationship with 
cardio-metabolic disease. 
 
Rs641738C>T near MBOAT7 (membrane bound O-acyltransferase domain 
containing 7) was initially identified as a genome-wide significant risk variant 
for alcohol-related cirrhosis (odds ratio=1.35, p=1.03 × 10−9) [3], though not 
replicated in a more recent analysis[4]. It has since been implicated in the 
pathogenesis of NAFLD[5], hepatocellular carcinoma[6], as well as in fibrosis 
development in chronic hepatitis B/C[7,8], and primary sclerosing 
cholangitis[9]. However, unlike variants in PNPLA3, TM6SF2, and 
HSD17B13, it was not identified at genome-wide significance for liver fat or 
ALT[1,10,11]. 
 
Rs641738 is located a few hundred base pairs downstream of the 3’ 
untranslated region of MBOAT7, which belongs to a family of genes that code 
for specific acyl donors and acceptors[12]. MBOAT7 encodes 
lysophosphatidylinositol acyltransferase 1 (LPIAT1), which contributes to the 
regulation of free arachidonic acid in cells[13,14]. Rs641738C>T is associated 
with lower hepatic expression of MBOAT7 at both the mRNA[15] and protein 
levels[5]. Given its role in inflammatory lipid pathways, most mechanistic work 













In NAFLD, the rs641738C>T variant was first demonstrated to be associated 
with increased hepatic fat content and severity of fibrosis in individuals of 
European descent[5]. Proton magnetic resonance spectroscopy data from 
2,736 individuals showed a modest increase in hepatic fat in those with TT-
genotype (4.1%) compared to those with CT- (3.6%) or CC-genotype (3.5%, 
p=0.005). Follow-up studies of European subjects corroborated the initial 
findings, and suggested a role in development of hepatocellular 
carcinoma[17,18]. However, these results were not replicated in adults of 
other ancestries[5,19–21] or in children[22]. 
 
In addition, bi-allelic loss of function mutations in MBOAT7 cause autosomal 
recessive mental retardation 57 (OMIM #617188) and no liver phenotype has 
been reported in these patients to date[14,23]. However, rare likely 
pathogenic (coding) variants in MBOAT7 are associated with HCC in 
NAFLD[24]. 
 
In summary, the association between rs641738C>T and hepatic fat content, 
as well as its effects on severity of NAFLD, remain unclear. Moreover, the 
broader metabolic effects of this SNV, including its association with markers 
of insulin resistance and dyslipidaemia have not been assessed. 
Understanding the broader metabolic effects of rs641738C>T is important if 













Here, we conducted a large meta-analysis to determine if rs641738C>T 














Data sources and study selection 
Two data sources were included in the meta-analysis: (i) studies which looked 
at the effect of the variant on traits of interest by genotyping the variant; and 
(ii) look-up from GWAS of traits of interest. 
Studies were sourced through: Medline, Embase, HuGe Navigator, Web of 
Science, bioRxiv, and medRxiv. The search terms used were: “(MBOAT7 or 
membrane-bound-o-acyltransferase) or (rs641738 or rs626283) or (TMC4)”. 
In addition, HuGe Navigator Phenopedia was searched using terms related to 
liver disease (Supplementary Methods). There were no restrictions on date or 
language. The search was completed on 28th July 2020. Reference lists of 
publications were also reviewed. 
A separate search was conducted for all potentially relevant GWAS through: 
GWAS Catalogue[25], Phenoscanner[26], Type 2 diabetes knowledge 
portal[27], and Cardiovascular disease knowledge portal[28] (Supplementary 
Methods). 
After removal of duplicates, titles and abstracts were screened for eligibility 
independently by two authors (investigators), with inclusion/exclusion criteria 
applied to potentially eligible full texts. 
 
HuGENet guidelines[29] were followed throughout and MOOSE reporting 
guidelines[30] were used. This study was prospectively registered on 
















Inclusion and exclusion criteria 
Studies were included if genotyping of rs641738C>T (or rs626283G>C 
[R2>0.98 in European and American populations[31]] / rs2576452C>T 
[R2=0.92 in Guzman et al. [32]], which are in strong linkage disequilibrium with 
rs641738C>T) was conducted and data on one of the outcomes of interest 
were reported. Narrative review articles, in vitro studies, and investigations 
involving animals, fish, and invertebrates were excluded. Studies which 
investigated liver disease of other aetiologies were also excluded. There was 
no restriction on ethnicity or ancestry. Types of studies eligible for inclusion 
were: case-control, cohort, genome-wide association studies, systematic 
reviews, and meta-analyses. Pre-print and abstract publications were not 
eligible for inclusion. Several studies reported on the same cohort (or patient 
sample) in more than one article. In these instances, data only from the larger 
of the overlapping cohorts were included in analyses. A full list of overlapping 
cohorts and articles is in Supplementary Table 1. 
 
Data collection 
Details on the recruitment of controls and cases were obtained from each 
study and, where necessary, clarified by discussion with the study’s authors. 
In particular, it was noted when cases and controls were not recruited from 












Hepatic steatosis or NAFLD (as diagnosis) was evaluated as a dichotomous 
variable where radiological (liver ultrasound, controlled attenuation parameter 
[CAP, with cut-off >248dB/m], CT, MRI) or histological assessment were 
used. Hepatic fat content was collected as a continuous variable from CT, 
MRS, MRI, PDFF. Non-invasive assessment of hepatic fat content was also 
assessed using semi-quantitative scoring in the Fenland cohort, as previously 
described[33], and using CAP. 
Individual participant-level histology data were extracted according to the 
NASH Clinical Research Network scoring system[34] and, where not 
otherwise diagnosed by a pathologist’s assessment, NASH was defined using 
the Fatty Liver Inhibition of Progression (FLIP) algorithm[35]. The above data 
were collected for each genotype separately (CC, CT, and TT). 
Participant demographics and characteristics meta-data were collected from 
each study, including: sex, age, ethnicity, presence of type 2 diabetes, body 
mass index (BMI). Where possible, individual patient-level data was obtained. 
The authors of 59 studies were contacted for additional data or clarification, of 
whom 49 replied. Data from 11 potentially relevant studies could not be 
included, which are listed in the Supplementary Methods. 
Additional details regarding cohorts with genome-wide data, the Avon 
Longitudinal Study of Parents and Children (ALSPAC) [36–38]data extracted 
from the UK BioBank, quality assessment, and statistical analysis is found in 
















Database search identified 1167 articles (Supplementary Fig. 1), of which 44 
articles were included: 42 primary studies (Supplementary Tables 2-4), one 
systematic review and one meta-analysis (Supplementary Table 5).  
In total, 1,066,175 individuals (5,711 children) were included in the meta-
analysis. Most studies were in adults (32/42, 76%) and in individuals from 
predominantly Caucasian populations (26/42, 62%). Of the 42 included 
studies, 14 studies (9,688 participants, hereof 584 children) reported data on 
liver histology. 
 
Studies were generally of high quality, though in five studies[11,22,39–41] 
(four in adults and one in children) the control group was recruited from a 
different population or sample to the cases (Supplementary Table 3). 
 
One previous meta-analysis was included[42], which used data from 5 case-
control studies to assess the effect of rs641738C>T on diagnosis of NAFLD. 
The meta-analysis included 2,560 cases and 8,738 controls and found no 
evidence of an association between this variant and diagnosis of NAFLD 
(Supplementary Table 5). One previous systematic review[43] found positive 
associations between rs641738C>T in adults of Caucasian, Hispanic, and 
African American descent with limited data in children (Supplementary Table 
5). 
 












Seven studies (29,679 participants) reported data on hepatic fat as a 
continuous variable assayed by CT or MRI. On meta-analysis, rs641738C>T 
was associated with higher liver fat in studies in Caucasian populations using 
an additive model of inheritance, with a per T-allele change of β 0.034 (95% 
CI 0.018, 0.051), pz=4.8x10
-5) standard deviations in inverse-normalized liver 
fat (Figure 1), whilst no consistent effect was observed in non-Caucasian 
populations. A similar trend was observed using a dominant model of 
inheritance in studies of Caucasian populations: mean difference in hepatic fat 
+0.18% ((95% CI 0.2, 0.34), pz=0.04, Supplementary Table 6). 
 
Given the difference in sensitivity and specificity of modalities used to assess 
liver fat, a sub-analysis by modality of imaging was performed. No significant 
differences were observed between studies using CT, MRI, or MRS for 
quantification of liver fat (Supplementary Figure 2). 
 
A similar trend was observed using CAP and semi-quantitative ultrasound to 
assess steatosis severity in 12,224 adults (β 0.02 (95% CI -0.002, 0.04), , 
pz=0.08, Supplementary Figure 3). 
 
Data from a range of diverse modalities was used to assess the effect of this 
variant on diagnosis of NAFLD, to reflect real-world diagnostic practice. 
rs641738C>T was associated with NAFLD as a trait (OR 1.15 (95% CI 1.05, 
1.26), pz=0.002) using a recessive model of inheritance (Figure 2) but not 
using additive or dominant models (Supplementary Table 7). The effect was 












1.3), pz=0.003). Sub-group analysis by modality of diagnosis found the 95% 
confidence intervals for all modalities overlapped, except for MRI-PDFF, 
which had only one study (Supplementary Figure 4).  The association 
remained after excluding four studies where there was a lack of similarity 
between cases and controls (OR 1.19 (95% CI 1.07, 1.33), pz=0.0017) using a 
recessive model of inheritance. 
 
However, Egger’s test suggested evidence of study distribution (publication) 
bias (p=0.013) and when using the Trim and Fill method to account for this 
bias, the positive association remained but was attenuated (OR 1.11 (95% CI 
1.01, 1.23), pz=0.037, Supplementary Figure 5). 
 
In patients with NAFLD, data from eight studies (6,206 participants) 
rs641738C>T was not significantly associated with the presence of severe 
steatosis (S1-2 vs. S3) on liver biopsy (OR 1.08 (95% CI 0.78, 1.5), Pz=0.64, 
Table 1 & Supplementary Figure 6). 
 
Histological NASH in adults 
Data from nine studies (7,719 participants) found that rs641738C>T was not 
associated with the presence of NASH on biopsy in adults (OR 1.24 (95% 
0.96, 1.36), pz=0.128 Supplementary Figure 7). 
 
Fibrosis in adults 
Liver biopsy data on presence of advanced fibrosis was available from eight 












adults (stage F0-2 versus stage F3-4), showed a borderline positive 
association with rs641738C>T in Caucasian populations (OR 1.22 (95% 1.03, 
1.45), pz=0.021)(Figure 3). In addition, two studies used ICD-codes 
(International Statistical Classification of Diseases and Related Health 
Problems) in the UKBB cohort to identify individuals with NAFLD and 
advanced fibrosis or cirrhosis[44,45]. Both found positive associations below 
genome-wide significance: for example, using an additive model of 
inheritance Emdin et al. found the association between rs641738C>T and 
cirrhosis as β 1.22 (SE 0.06, P=0.03), using an additive genetic model. 
 
Data from nine studies (8,389 participants), found that presence of any 
fibrosis (F0 versus F1-4) was also borderline positively associated with 
rs641738C>T overall (OR 1.27 (95% 1.04, 1.54), pz=0.018) as well as in non-
Caucasian populations as a sub-group (Supplementary Figure 8). 
 
Development of hepatocellular carcinoma 
Four cohorts (2,328 participants, 228 cases of NAFLD-HCC) reported on 
development of HCC in patients with NAFLD. rs641738C>T was associated 
with increased odds of HCC in NAFLD only when using a dominant model 
(CC vs. CT+TT) of inheritance (OR 1.64 (95% CI 1.18, 2.27), pz=0.003, Figure 
4). 
 
Effect on alanine aminotransferase (ALT) 
Data from GWAS using log-transformed ALT (609,794 participants) were 












The variant showed a positive association with ALT (β 0.004 (95% CI 0.002, 
0.007), pz=0.002), which on sub-analysis was observed in Caucasian 
populations but not in non-Caucasian populations (Figure 5 & Supplementary 
Table 7). 
 
Additionally, in the UKBB cohort, rs641738C>T was associated with a small, 
but statistically significant (P=2.0x10-8) increase in un-transformed ALT: 
0.18 IU/L higher ALT per T-allele in this variant (Supplementary Table 8). 
 
In the remaining cohort and case-control studies included in the meta-analysis 
(15,208 adults), rs641738C>T was not found to be significantly associated 
with a change in ALT, for example mean difference using a recessive model 
(CC+CT vs. TT) +0.32 IU/L (95% CI -0.06, 0.7), pz=0.08, Supplementary 
Table 9) in Caucasian populations. 
 
Effect on serum lipids and insulin 
Data from GWAS using log-transformed serum triglycerides (850,241 
participants) found that rs641738C>T was associated with lower triglycerides 
(β -0.01 (95% CI -0.018, -0.006), pz=1.5x10
-4), which on sub-analysis was 
observed in Caucasian populations but not in non-Caucasian populations 
(Supplementary Fig. 9). Similar findings were obtained from meta-analysis of 
cohort and case control studies, particularly using an additive model (β -0.03 













Data from GWAS (852,409 participants) found rs641738C>T to be positively 
associated with total cholesterol , in Caucasian populations (β 0.007 (95% CI 
0.003, 0.01), pz=2.1x10
-4), which was not observed in non-Caucasian 
populations (Supplementary Fig. 10). A borderline positive association was 
also observed between rs641738C>T and high-density lipoprotein (HDL) 
cholesterol (β 0.009 (95% CI 0.001, 0.02), pz=0.02), Supplementary Table 7). 
There was no effect on fasting insulin levels found in population-level GWAS 
(β 0.009 (95% CI -0.03, 0.04), pz=0.64), Supplementary Table 7). However, a 
negative association was observed using data from cohort and case-control 
studies with a dominant genetic model (mean difference -1.4 pmol/L (95% CI -
2.1, -0.65), pz=0.004), Supplementary Table 9). 
 
Effect of rs641738C>T on paediatric NAFLD 
Data from ten studies (5,711 children) was used in the meta-analysis. 
rs641738C>T was not significantly associated with the diagnosis of NAFLD, 
liver fat content, stage of liver histology, or serum biochemistry 
(Supplementary table 10). 
 
Meta-regression shows interaction between rs641738C>T and type 2 
diabetes 
Finally, we aimed to determine whether baseline participant characteristics 
influenced the association of rs641738C>T on histological outcomes using 
meta-regression. There was a negative association with presence of type 2 
diabetes and effect size for NASH vs. NAFL (β -1.8 (standard error 0.65), 












diabetes was observed for severe steatosis (S1-2 vs. S3, β -2.6 (standard 
error 1.5), p=0.08) and presence of fibrosis (F0 vs. F1-4, β -1.5 (standard 
error 0.8), p=0.06, Supplementary Table 11). In addition, effect size for any 
fibrosis was greater in cohorts with an older mean age (β 0.05 (standard error 













Identification of genetic variants associated with NAFLD has the potential to 
inform pre-clinical research and our understanding of hepatic metabolism. In 
this meta-analysis we have validated rs641738C>T near MBOAT7 as a risk 
factor for the full spectrum of NAFLD in Caucasian adults. 
 
A two-stage GWAS initially identified rs641738C>T as a genome-wide 
significant locus for alcohol-related cirrhosis[3]. MBOAT7 was a potentially 
interesting target as an enzyme involved in (phospho)lipid metabolism, 
conceptually similar to other SNVs at GWAS-significance in alcoholic and 
non-alcoholic liver disease, namely TM6SF2 and PNPLA3. Later studies 
found the variant to influence the full spectrum of fatty liver disease, from 
steatosis to NASH, to fibrosis, cirrhosis and HCC[5,17]. However, these 
associations have not been consistently replicated in the literature[19]. We 
conducted a meta-analysis to firmly establish the association of rs641738C>T 
with the presence and severity of NAFLD, and associated metabolic traits. 
 
Main findings 
We found that rs641738C>T was associated with higher liver fat content, 
higher ALT, and with higher odds of NAFLD diagnosis, fibrosis, and HCC, 
particularly in Caucasian adults and in the homozygous ‘TT’ genotype. The 
effects sizes of rs641738C>T reported here are small compared to those of 
PNPLA3 p.I148M and TM6SF2 p.E167K, the two strongest steatogenic 
variants[46]. Also, the magnitude of change in alanine aminotransferase is 












MTARC1, and TM6SF2. This may account for the absence of this variant (or 
others near MBOAT7) from GWAS for NAFLD in the general 
population[1,10,11,45,47] the effect size (and associated p-value) was too 
small to be identified as significant genome-wide. The marginal positive effect 
on hepatic triglyceride content may suggest this variant acts through 
alterations in the composition of hepatic lipid, as well as quantity[17]. This is 
consistent with pre-clinical data on lipotoxicity, where the composition of 
hepatic fats influence development of NASH. On the other hand, a recent 
Mendelian randomization study using these variables as instruments to 
assess causality of fatty liver in determining fibrosis has shown the effect of 
steatosis highly correlates with fibrosis in all the genetic variables indicating 
that quantity of lipid rather than quality may be more important[48]. Functional 
studies are needed to understand the relationship between quality/quantity of 
fat and hepato-toxic/-protective mechanism in causing progression of disease. 
 
The function of this variant is still relatively poorly understood and there is 
conflicting evidence as to whether rs641738C>T is associated with changes in 
hepatic expression of MBOAT7. Results from the GTEx Consortium show a 
strong negative association with T-allele[15], which is supported by data from 
Schadt et al.[49]. MBOAT7 protein expression correlated with mRNA in liver 
biopsies from Mancina et al.[5] but this finding was not replicated by Sookoian 
et al.[19]. MBOAT7 encodes LPIAT1, a 6 transmembrane domain protein 
involved in acyl-chain remodelling of membranes that influence intracellular 
membrane composition and circulating phosphatidylinositols[50]. Further, 












this SNV[51]. Moreover, TMC4 was found with a low expression in the liver[5] 
that is consistent with no mechanistic data supporting its role in NAFLD.  
 
The hypothesis that MBOAT7 is the causal gene underlying the association 
with liver disease at the locus is supported by the observation that mice 
deficient for MBOAT7 have altered hepatic concentrations of polyunsaturated 
phosphatidylinositol[50]. Similarly, metabolite data from humans is strongly 
suggestive that rs641738C>T reduces MBOAT7 function[52]. In addition, two 
independent groups have found that loss of MBOAT7 (but not TMC4) 
increases the severity of NAFLD in mice fed a high-fat diet[53,54].  
 
These analyses suggest that rs641738C>T impacts the severity of NAFLD 
through a recessive model of inheritance, though some analyses (e.g. liver fat 
and ALT) were suggestive of a role using an additive genetic model. Other 
genetic variants are known to impact on all-cause mortality in a recessive 
manner, notably variants that perturb HFE[44]. Further mechanistic work is 
required to understand the extent to which the haplo-insufficient state affects 
hepatocyte function. 
 
We found no evidence of an effect of rs641738C>T on insulin resistance: the 
key driver of hepatic steatosis, as determined by unaltered fasting insulin 
concentrations. GWAS meta-analyses of type 2 diabetes have implicated 
p.I148M in PNPLA3 and p.E167K in TM6SF2 as significant risk loci (albeit 
with very modest effect size as compared to their effects on liver disease)[55] 












insulin resistance mediated by the degree of liver damage[48,56]. Similarly, 
these two variants are associated with reduced risk of coronary artery 
disease; whilst our analysis did find lower serum triglycerides to be associated 
with this variant it has not been associated with lower rates of cardiovascular 
disease[57]. However, we did observe a negative association between effect 
size and prevalence of diabetes on meta-regression, potentially suggesting 
that this variant has the greatest effect in less insulin-resistant individuals. 
 
A strength of this meta-analysis is the large number of individuals with liver 
biopsy-derived phenotypic data as well as use of population-based GWAS 
data. The larger number of included studies and participants is likely to 
account for the different conclusions reached in this study compared to the 
previous meta-analysis by Xia et al.[42]. 
 
Limitations and quality of evidence 
An important practical consideration is the population frequency of this variant 
in different ethnicities. The mean allelic frequency of the effect (T) allele is 
highly variable: from 0.24 in East Asians compared to 0.53 in those of South 
Asian ancestry[58]. Moreover, the majority of studies included in this meta-
analysis used self-reported ethnicity, rather than genetic ancestry. 
 
Though this analysis did include data from individuals of multiple ethnicities 
(and genetic ancestries) we only found evidence of an effect of this variant in 
Caucasian individuals. This is consistent with the initial discovery and it is 












differences in patterns of linkage disequilibrium, we cannot exclude the 
possibility that a different nearby locus is associated with liver-related 
phenotypes in individuals of other genetic ancestries. 
 
A limitation of using meta-analysis for a single variant is the lack of adjustment 
for population stratification. When further genome-wide data are available, a 
formal GWAS meta-analysis may be able to address this. 
 
We found significant differences between adult and paediatric histological 
analyses. Whilst there were fewer clinical events (e.g. with advanced fibrosis) 
in children, the analyses did not show a trend congruous with those in adults. 
Paediatric NAFLD has a different histological phenotype to that of adults (with 
prominent periportal inflammation) and it is therefore plausible that this is a 
true lack of association in children with NAFLD. 
 
Data from multiple diagnostic or imaging modalities were combined in several 
analyses. Though we observed minimal heterogeneity between modalities, 
these techniques have differing accuracy for diagnosis of steatosis, which has 
the potential to affect results. The sub-group analysis of hepatic fat by 
modality suggested a marginally greater effect size in studies using MRS, 
which is regarded as a highly sensitive technique. There is potential that 
through inclusion of other modalities (e.g. CT) we have underestimated the 













The magnitude of effect observed across all associations is small in 
comparison to other well-established variants. The clinical relevance of 
rs738409C>G in PNPLA3 has been validated with hard end-points[59] but 
large cohorts will be required to prospectively demonstrate the clinical risk 
associated with this variant near MBOAT7. 
 
Though there was minimal heterogeneity across included studies, there was 
evidence of publication bias but the effect on diagnosis of NAFLD appeared to 
persist after attempting to account for this. Also of note, the numbers of 
individuals with NAFLD and HCC were comparatively low, also limiting the 
power to assess for an association of this variant with non-cirrhotic HCC, as 
has been previously reported[6]. The HCC analysis was also unique in only 
demonstrating an effect in the dominant, rather than recessive, model of 




rs641738C>T near MBOAT7 is positively associated with liver fat, ALT, and 
histological severity in Caucasian adults with NAFLD, but negatively 
associated with serum triglycerides and with relatively small effect sizes 
throughout. These data validate this locus as significant in the pathogenesis 














ALSPAC, Avon Longitudinal Study of Parents and Children; ALT, alanine 
aminotransferase; BMI, body mass index; CAP, controlled attenuation 
parameter; CT, computed tomography; GWAS, genome-wide association 
study; HFE, homeostatic iron regulator protein; HOMA-IR, homeostatic model 
assessment of insulin resistance; HSD17B13, 17β-Hydroxysteroid 
dehydrogenase type 13; MBOAT7, membrane bound O-acyltransferase 
domain containing 7; MTARC1, Mitochondrial amidoxime reducing component 
1; OR, odds ratio; MRI-PDFF, magnetic resonance imaging-proton density fat 
fraction; MRS, magnetic resonance spectroscopy; PNPLA3, patatin-like 
phospholipase domain containing protein 3; SNV, single nucleotide variant; 
TM6SF2, transmembrane 6 superfamily member 2; TMC4, transmembrane 
channel-like 4; UKBB, UK BioBank. 
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Table 1. Summary of results in adults from meta-analyses for 
dichotomous outcomes. Meta-analyses were performed using random 
effects with subgroup analysis for Caucasian and Non-Caucasian populations. 
Additive, recessive, and dominant genetic models were tested for all 
outcomes. Results using a recessive model of inheritance (CC+CT vs. TT) are 
shown for all outcomes, except for HCC, where a dominant model (CC vs. 
CT+TT) is shown. Due to use of three genetic models, critical p-value for 
effect summary is pz<0.017. Full results (with all genetic models) are in 
Supplementary Table 5. CI, confidence interval; HCC, hepatocellular 
carcinoma; NAFL, non-alcoholic fatty liver; NASH, non-alcoholic 















Fig. 1. The effect of rs641738C>T on liver fat. Data from 29,679916 
individuals with CT, or MRI, or MRS liver fat. rs641738C>T positively 
associated with liver fat in Caucasian populations, where data represents 
standard deviation change in normalized liver fat per T-allele. CI, confidence 
interval; UKBB, UK BioBank. 
 
Fig. 2. rs641738C>T is associated with higher odds of diagnosis of 
NAFLD. Data from 52,17333,263 adults (11,3019,713 cases and 
40,87223,550 controls) with radiologically or histologically defined steatosis 
for presence versus absence of NAFLD. CI, confidence interval; LBC, Liver 
Biopsy Cohort; OR, odds ratio. 
 
Fig. 3. The effect of rs641738C>T on presence of advanced fibrosis in 
adult patients with NAFLD. Data from 7,6926,211 adults (1,214828 cases 
and 6,4785,383 controls) with biopsy-proven NAFLD comparing advanced 
fibrosis (F3-4) versus F0-2, using a recessive model of inheritance (CC+CT 
vs. TT). CI, confidence interval; LBC, Liver Biopsy Cohort; OR, odds ratio. 
 
Fig. 4. rs641738C>T is associated with higher odds of NAFLD-HCC. Data 
from 2,328 adults with NAFLD assessing for the presence versus absence of 













Fig. 5. rs641738C>T is positively associated with alanine 
aminotransferase (ALT) in Caucasian populations in genome-wide 
association studies (GWAS). Meta-analysis of GWAS summary statistics 
from 609,794 participants for the association between rs641738C>T on 
logarithmically-transformed ALT using linear regression. CI, confidence 












Heterogeneity: I2 = 0%, p = 7.25e−01
Residual heterogeneity: I
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 = 0%, p = 6.58e−01
Test for overall effect: z = 4.38 (p = 1.20e−05)
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 = 31%, p = 2.36e−01
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Test for effect in subgroup: z = 0.95 (p = 3.40e−01)
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Recessive model − overall effect
Heterogeneity: I2 = 25%, τ2 = 0.0072, p = 1.67e−01
Residual heterogeneity: I
2
 = 29%, p = 1.29e−01
Test for overall effect: z = 3.12 (p = 1.83e−03)
Ethnicity = Caucasian    
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Recessive model − overall effect
Recessive model − overall effect
Heterogeneity: I
2
 = 38%, τ2 = 0.0106, p = 9.03e−02
Heterogeneity: I
2
 = 0%, τ2 = 0, p = 4.60e−01
Test for effect in subgroup: z = 2.94 (p = 3.28e−03)


































































   8

















   66





   94
No NAFLD

























[1.05;    1.26]
[1.05;    1.30]
[0.90;    1.34]
[0.75;    1.18]
[0.77;    1.45]
[0.82;    1.37]
[0.95;    1.23]
[0.97;    1.23]
[0.91;    2.15]
[0.98;    2.09]
[1.02;    2.06]
[0.98;    2.49]
[1.09;    2.38]
[1.21;   10.32]
[0.01; 1583.86]
[0.67;    1.30]
[0.67;    1.60]
[0.59;    1.85]
[0.94;    1.98]































Recessive model − overall effect
Heterogeneity: I2 = 0%, τ2 = 0, p = 0.65
Residual heterogeneity: I2 = 0%, p = 0.60
Test for overall effect: z = 2.21 (p = 0.027)
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Heterogeneity: I2 = 0%, τ2 = 0, p = 0.64
Test for effect in subgroup: z = 2.31 (p = 0.021)
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Recessive model − overall effect
Heterogeneity: I2 = 0%, τ2 = 0, p = 0.95


























































Heterogeneity: I2 = 0%, p = 0.71
Residual heterogeneity: I2 = 0%, p = 0.63
Test for overall effect: z = 3.07 (p = 0.002)




Heterogeneity: I2 = 34%, p = 0.18
Heterogeneity: I2 = 0%, p = 0.97
Test for effect in subgroup: z = 2.08 (p = 0.038)
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